Actinium Pharmaceuticals, Inc. (ATNM)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total revenue-Other Revenue | - | - | - | |
| Research and development, net of reimbursements | 4,879 | 9,774 | 8,825 | |
| General and administrative | 2,624 | 2,827 | 3,593 | |
| Total operating expenses | 7,503 | 12,601 | 12,418 | |
| Total revenue-Revenue | - | - | - | |
| Total revenue | - | - | - | |
| Loss from operations | -7,503 | -12,601 | -12,418 | |
| Interest income - net | 625 | 1,033 | 1,065 | |
| Total other income | 625 | 1,033 | 1,065 | |
| Net loss | -6,878 | -11,568 | -11,353 | |
| Net loss per common share basic (in dollars per share) | -0.22 | -0.37 | -0.38 | |
| Net loss per common share diluted (in dollars per share) | -0.22 | -0.37 | -0.38 | |
| Weighted average common shares outstanding basic (in shares) | 31,195,891 | 31,071,297 | 30,103,063 | |
| Weighted average common shares outstanding diluted (in shares) | 31,195,891 | 31,071,297 | 30,103,063 | |